(2-Hydroxy-5-oxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2-Hydroxy-5-oxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate
• 英文别名: (2-hydroxy-5-oxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate
• 化学式: C₁₄H₁₈N₂O₆
• 分子量: 310.3
• InChiKey: CSGLODXZJBQVSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  104
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• ANTIBODY-DRUG CONJUGATE, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

  公开号：EP3991754A1

  公开（公告）日：2022-05-04

  Disclosed are an antibody-drug conjugate (ADC), an intermediate thereof, a preparation method therefor and an application thereof. The present invention provides an ADC. A structural general formula thereof is Ab-(L 3-L 2-L 1-D)m. The ADC has better biological activity, stability, and uniformity, has reduced toxic and side effects, and has a faster release rate of enzyme cutting in tumor cells. The use of the novel ADC can achieve a wide application of a cytotoxic drug particularly camptothecin in the field of ADCs in treating tumor patients resistant to microtubule ADC.

  本发明公开了一种抗体药物共轭物（ADC）、其中间体、制备方法及其应用。本发明提供了一种 ADC。其结构通式为Ab-(L 3-L 2-L 1-D)m。该ADC具有较好的生物活性、稳定性和均一性，毒副作用较小，在肿瘤细胞中的酶切释放速度较快。使用该新型 ADC 可以实现细胞毒性药物尤其是喜树碱在 ADC 领域的广泛应用，治疗对微管 ADC 耐药的肿瘤患者。
• Antibody-drug-conjugate and its use for the treatment of cancer
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US10314921B2

  公开（公告）日：2019-06-11

  The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

  本发明涉及一种抗体-药物共轭物。从一个方面来说，本发明涉及一种抗体-药物-共轭物，该抗体-药物-共轭物包括能够与靶标结合的抗体，所述抗体与至少一种选自多拉他汀 10 和曙红的衍生物的药物共轭。本发明还包括治疗癌症的方法和使用所述抗体-药物-共轭物的方法。
• Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
  申请人：Pfizer Inc.

  公开号：US10376531B2

  公开（公告）日：2019-08-13

  Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

  本文描述了式(A)化合物及其在治疗由药物组合物介导的疾病、病症和/或失调方面的用途，以及其作为淀粉糖蛋白受体（ASGPR）靶向制剂的用途。
• [EN] CYCLIC DINUCLEOTIDE STING AGONISTS TETHERED TO A PD-1 OR CTLA-4 ANTIBODIES<br/>[FR] AGONISTES DE STING DINUCLÉOTIDIQUES CYCLIQUES ATTACHÉS À UN PD-1 OU À DES ANTICORPS CTLA-4
  申请人：SPEROVIE BIOSCIENCES INC

  公开号：WO2021046426A9

  公开（公告）日：2022-02-17
• ANTI-HER2 ANTIBODY-DRUG CONJUGATE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3101032B1

  公开（公告）日：2019-01-16